Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Growject to Enter PIII Study for SHOX Deficiency: JCR
May 21, 2018
- Kyowa Kirin’s Burosumab Hits Primary Endpoint in Multinational PIII Study in XLH Children including Japan
May 21, 2018
- Nobelpharma Becomes Medipal’s Equity Method Affiliate
May 21, 2018
- Talion Authorized Generics Rack Up 1.5 Billion Yen in Single Month
May 18, 2018
- Fujifilm’s Cancer Peptide Vaccine Flops in Japan PIII
May 18, 2018
- Sawai Seeks Strategical Alliance, Intra-Industry Network under New Midterm Biz Plan
May 18, 2018
- 10 Major Japan Drug Makers’ Sales Up 3.3%, but Decline Expected for FY2018 on Price Revision
May 18, 2018
- Alecensa Approved for 1st-Line Treatment of NSCLC in Taiwan: Chugai
May 17, 2018
- Daiichi Sankyo, Canadian Biotech Expand Joint Research on Bispecific Antibodies
May 16, 2018
- Gilead Seeks Japan Approval for Epclusa
May 16, 2018
- Towa Aims at Expansion into US and ASEAN Markets, Annual Sales of 100 Billion Yen under New 3-Year Plan
May 16, 2018
- Nichi-Iko, Eisai to Copromote Partner’s Generics from October
May 16, 2018
- Eisai Poised to Focus on Maximization of Lenvima Value: CEO
May 16, 2018
- Eisai Chalks Up 1st Double-Digit Growth in 11 Years on Merck Deal, Global Brands
May 16, 2018
- Taisho to Launch Voluntary Redundancy Program
May 15, 2018
- Velcade Sales Would Slide 50%, but Weber Stresses Takeda’s Strong Momentum
May 15, 2018
- Taisho and Fujifilm to Dissolve Capital Alliance and Transform Their JV Companies to Wholly Owned Subsidiaries
May 15, 2018
- Takeda Delivers Double-Digit Profit Growth as Entyvio Nets 200-Plus Billion Yen
May 15, 2018
- Lilly, Sapporo Medical Univ. Ink Antigen Research Deal for Colorectal Cancer Immunotherapy
May 14, 2018
- Santen Plans Add’l Trial on Uveitis Treatment DE-109 after FDA Rebuff
May 14, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…